Methipred 8

Presentation: Each tablet contains 8 mg of methylprednisolone.

Indications: Methipred 8 is a corticosteroid indicated for the treatment of a wide range of inflammatory and autoimmune conditions, including:

• Endocrine disorders: Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.  
• Rheumatic disorders: As adjunctive therapy for short-term administrationin acute episodes of psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis.
• Collagen diseases: Systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis.  
• Dermatologic diseases: Pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme,exfoliative dermatitis, severe psoriasis, severe seborrheic dermatitis.  
• Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventionaltreatment in seasonal or perennial allergic rhinitis, serum sickness,contact dermatitis, atopic dermatitis, drug hypersensitivity reactions, transfusion reactions, acute noninfectious laryngeal edema.
• Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes zoster ophthalmicus, iritis and iridocyclitis,chorioretinitis, diffuse posterior uveitis and choroiditis,optic neuritis.
• Respiratory diseases: Symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when usedconcurrently with appropriate antituberculous chemotherapy, aspiration pneumonitis.  
• Hematologic disorders:Acquired (autoimmune) hemolytic anemia, idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, erythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic anemia.  
• Neoplastic diseases: For palliative management of leukemias and lymphomas.  
• Edematous states: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.  
• Gastrointestinal diseases:To tide the patient over a critical periodof ulcerative colitis and regional enteritis.  
• Nervous system: Acute exacerbations of multiple sclerosis.  
• Miscellaneous: Tuberculous meningitis with subarachnoidblock or impending block when used concurrently with appropriate antituberculous chemotherapy,trichinosis with neurologic or myocardial involvement.  

Dosage and Administration:   The initial dosage of Methipred 8 may vary depending on the specific disease being treated. In less severe diseases, lower doses will generally suffice, while in severe diseases, higher initial doses may be required. The initial dose should be maintained or adjusted until a satisfactory response isnoted. If after a reasonable period there is a lack of satisfactory clinical response,methylprednisolone should be discontinued and the patient transferred to other appropriatetherapy.

The usual initial adult dosage may range from 4 mg to 48 mg per day. For specific conditions, higher doses may be used.

Methipred 8 tablets are for oral administration and should be swallowed whole with water. It is generally recommended to take the daily dose once in the morning to coincide with the body's natural cortisol secretion rhythm. However, in some cases, divided doses may be necessary.

Following a favorable response, the maintenance dose should be determined by gradually reducing the initial dose at reasonable intervals until the lowest dose that maintains an adequate clinical response is reached. Dosage requirements may change in situations of stress (e.g., surgery, trauma, infection).

Side Effects: Prolonged use of corticosteroids like Methipred 8 can lead to a variety of systemic side effects, including:

• Fluid and electrolyte disturbances: Sodium retention, fluid retention, potassium loss, hypokalemic alkalosis, hypertension.  
• Musculoskeletal: Muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones.  
• Gastrointestinal: Peptic ulcer with possiblehemorrhage and perforation, pancreatitis, abdominal distension, ulcerative esophagitis.  
• Dermatologic: Impaired wound healing, thin fragile skin, petechiae and ecchymoses, facialerythema, increased sweating.
• Neurologic: Convulsions, increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment withdrawal, vertigo, headache.  
• Endocrine: Menstrual irregularities, development of Cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics.  
• Ophthalmic: Posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos.  
• Metabolic: Negative nitrogen balance due to protein catabolism.  
• Psychiatric: Euphoria, mood swings,depression, psychotic reactions.
• Other: Increased susceptibility to infection, masking of infections, reactivation of latent infections.

Precautions: Methipred 8 should be used with caution in patients with heart failure, hypertension, diabetes mellitus, glaucoma, epilepsy, peptic ulcer, osteoporosis, psychotic tendencies, renal insufficiency, tuberculosis (active or latent), and systemic fungal infections.

Corticosteroids can mask signs of infection and may exacerbate fungal or viral infections.

Prolonged corticosteroid therapy may suppress the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal insufficiency upon withdrawal. Withdrawal should be gradual.

Live or live attenuated vaccines should not be administered to patients receiving immunosuppressive doses of corticosteroids.

In children, corticosteroid therapy may retard growth. Growth should be monitored.

Inform healthcare professionals about all other medications being taken, including over-the-counter drugs and herbal supplements, as interactions may occur (e.g., with NSAIDs, anticoagulants, diuretics, antidiabetic agents, some antibiotics and antifungals).

The use of Methipred 8 during pregnancy should be carefully considered, and it should be used only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefullyobserved for signs of hypoadrenalism.Corticosteroids are excreted in breast milk and may suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects in the nursing infant.